Ani Pharmaceutic Financials
This page shows Ani Pharmaceutic (ANIP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Ani Pharmaceutic has an operating margin of 0.1%, meaning the company retains $0 of operating profit per $100 of revenue. This below-average margin results in a low score of 1/100, suggesting thin profitability after operating expenses. This is down from 9.7% the prior year.
Ani Pharmaceutic's revenue surged 26.2% year-over-year to $614.4M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Ani Pharmaceutic carries a low D/E ratio of 0.77, meaning only $0.77 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 83/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.72, Ani Pharmaceutic holds $2.72 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 89/100.
Ani Pharmaceutic has a free cash flow margin of 7.8%, earning a moderate score of 39/100. The company generates positive cash flow after capital investments, but with room for improvement.
Ani Pharmaceutic scores 1.90, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.7B) relative to total liabilities ($855.2M). This signals moderate financial risk that warrants monitoring.
Ani Pharmaceutic passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Ani Pharmaceutic generates $-3.46 in operating cash flow ($64.0M OCF vs -$18.5M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Ani Pharmaceutic earns $0.0 in operating income for every $1 of interest expense ($584K vs $33.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Ani Pharmaceutic generated $614.4M in revenue in fiscal year 2024. This represents an increase of 26.2% from the prior year.
Ani Pharmaceutic's EBITDA was $68.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 36.0% from the prior year.
Ani Pharmaceutic generated $47.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 56.6% from the prior year.
Ani Pharmaceutic reported -$18.5M in net income in fiscal year 2024. This represents a decrease of 198.6% from the prior year.
Ani Pharmaceutic earned $-1.04 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 222.4% from the prior year.
Ani Pharmaceutic held $144.9M in cash against $309.1M in long-term debt as of fiscal year 2024.
Ani Pharmaceutic's gross margin was 59.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 3.4 percentage points from the prior year.
Ani Pharmaceutic's operating margin was 0.1% in fiscal year 2024, reflecting core business profitability. This is down 9.6 percentage points from the prior year.
Ani Pharmaceutic's net profit margin was -3.0% in fiscal year 2024, showing the share of revenue converted to profit. This is down 6.9 percentage points from the prior year.
Ani Pharmaceutic invested $44.6M in research and development in fiscal year 2024. This represents an increase of 30.0% from the prior year.
Ani Pharmaceutic spent $11.0M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 119.8% from the prior year.
Ani Pharmaceutic invested $16.2M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 83.1% from the prior year.
ANIP Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $227.8M+7.8% | $211.4M+7.2% | $197.1M+3.4% | $190.6M+38.1% | $138.0M+0.4% | $137.4M+4.4% | $131.7M-0.1% | $131.8M |
| Cost of Revenue | $93.4M+25.2% | $74.6M+2.2% | $73.0M-9.0% | $80.3M+39.1% | $57.7M+17.4% | $49.2M-8.0% | $53.4M+11.1% | $48.1M |
| Gross Profit | $134.4M-1.7% | $136.8M+10.2% | $124.1M+12.5% | $110.3M+37.3% | $80.3M-9.0% | $88.3M+12.8% | $78.2M-6.6% | $83.7M |
| R&D Expenses | $12.3M-25.6% | $16.5M+56.5% | $10.6M-36.5% | $16.6M+128.2% | $7.3M-30.6% | $10.5M+6.5% | $9.9M-11.3% | $11.1M |
| SG&A Expenses | $76.7M-6.3% | $81.8M+6.9% | $76.5M+9.8% | $69.7M+32.0% | $52.8M+10.0% | $48.0M+8.0% | $44.5M+5.8% | $42.0M |
| Operating Income | $36.2M+160.9% | $13.9M-47.0% | $26.2M+698.3% | -$4.4M-184.7% | $5.2M-74.6% | $20.3M+202.0% | $6.7M-62.5% | $17.9M |
| Interest Expense | $8.3M+0.7% | $8.2M+1.4% | $8.1M-7.9% | $8.8M-3.0% | $9.1M-0.4% | $9.1M-20.6% | $11.5M+37.9% | $8.3M |
| Income Tax | $7.2M+263.5% | $2.0M-54.1% | $4.3M+223.5% | -$3.5M | $0-100.0% | $7.1M+3526.9% | -$208K-113.2% | $1.6M |
| Net Income | $26.6M+211.3% | $8.5M-45.5% | $15.7M+252.6% | -$10.3M-349.3% | -$2.3M-112.6% | $18.2M+1476.4% | $1.2M-88.4% | $9.9M |
| EPS (Diluted) | $1.13+213.9% | $0.36-47.8% | $0.69+253.3% | $-0.45-221.4% | $-0.14-117.1% | $0.82+1540.0% | $0.05-88.9% | $0.45 |
ANIP Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+4.9% | $1.3B+3.9% | $1.3B+0.7% | $1.3B+39.4% | $920.8M+0.7% | $914.5M+1.1% | $904.4M+1.6% | $889.9M |
| Current Assets | $698.4M+15.9% | $602.6M+12.4% | $536.3M+1.6% | $527.7M-5.0% | $555.5M+2.8% | $540.6M+4.0% | $519.8M+4.5% | $497.2M |
| Cash & Equivalents | $262.6M+20.6% | $217.8M+45.4% | $149.8M+3.4% | $144.9M-39.7% | $240.1M+5.0% | $228.6M+3.4% | $221.1M+14.5% | $193.1M |
| Inventory | $146.5M+5.9% | $138.3M+0.7% | $137.4M+0.5% | $136.8M+9.0% | $125.4M+10.2% | $113.8M+2.4% | $111.2M+4.3% | $106.6M |
| Accounts Receivable | $252.6M+11.9% | $225.7M+2.4% | $220.3M-0.6% | $221.7M+33.5% | $166.1M-3.7% | $172.4M+6.4% | $162.1M-9.4% | $178.8M |
| Goodwill | $62.5M+3.2% | $60.5M-0.2% | $60.7M+1.1% | $60.0M+112.6% | $28.2M0.0% | $28.2M0.0% | $28.2M0.0% | $28.2M |
| Total Liabilities | $902.3M+2.4% | $881.4M+3.8% | $849.0M-0.7% | $855.2M+94.3% | $440.1M+0.6% | $437.7M-2.0% | $446.8M+2.7% | $435.2M |
| Current Liabilities | $270.6M+14.2% | $236.8M+17.4% | $201.8M+4.2% | $193.7M+38.4% | $140.0M+2.3% | $136.9M-5.9% | $145.5M+8.3% | $134.4M |
| Long-Term Debt | $297.7M-1.3% | $301.5M-1.2% | $305.3M-1.2% | $309.1M+8.7% | $284.4M-0.1% | $284.6M-0.1% | $284.8M-0.1% | $285.0M |
| Total Equity | $505.8M+15.8% | $436.8M+4.3% | $418.6M+3.7% | $403.7M-11.4% | $455.8M+0.8% | $452.0M+4.4% | $432.7M+0.7% | $429.9M |
| Retained Earnings | -$50.6M+34.2% | -$76.9M+9.6% | -$85.0M+15.2% | -$100.3M-54.2% | -$65.0M-4.3% | -$62.3M+22.2% | -$80.1M+0.9% | -$80.9M |
ANIP Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $44.1M-41.9% | $75.8M+116.7% | $35.0M+120.6% | $15.9M-8.9% | $17.4M-4.7% | $18.3M-59.2% | $44.7M+39.1% | $32.2M |
| Capital Expenditures | $6.1M+52.0% | $4.0M+62.2% | $2.5M+3.3% | $2.4M-46.2% | $4.4M-2.9% | $4.6M+101.0% | $2.3M+31.1% | $1.7M |
| Free Cash Flow | $38.0M-47.1% | $71.8M+120.8% | $32.5M+141.5% | $13.5M+3.9% | $13.0M-5.3% | $13.7M-67.8% | $42.5M+39.5% | $30.4M |
| Investing Cash Flow | -$6.2M+10.8% | -$6.9M+65.2% | -$19.8M-85.8% | -$10.7M-140.1% | -$4.4M-149.8% | $8.9M+286.9% | -$4.8M-5.0% | -$4.6M |
| Financing Cash Flow | $6.3M+463.2% | -$1.7M+82.4% | -$9.9M-101.9% | -$4.9M-237.9% | -$1.5M+92.6% | -$19.7M-65.5% | -$11.9M-417.4% | $3.8M |
| Dividends Paid | $344K-15.5% | $407K+0.2% | $406K0.0% | $406K-0.2% | $407K+0.2% | $406K0.0% | $406K0.0% | $406K |
| Share Buybacks | $1.0M+89.5% | $551K-94.5% | $10.0M+3045.6% | $318K-75.5% | $1.3M-85.0% | $8.7M+3649.4% | $231K-65.5% | $670K |
ANIP Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.0%-5.7pp | 64.7%+1.8pp | 62.9%+5.1pp | 57.9%-0.3pp | 58.2%-6.0pp | 64.2%+4.8pp | 59.4%-4.1pp | 63.5% |
| Operating Margin | 15.9%+9.3pp | 6.6%-6.7pp | 13.3%+15.6pp | -2.3%-6.0pp | 3.7%-11.0pp | 14.8%+9.7pp | 5.1%-8.5pp | 13.6% |
| Net Margin | 11.7%+7.6pp | 4.0%-3.9pp | 8.0%+13.3pp | -5.4%-3.7pp | -1.7%-14.9pp | 13.3%+12.4pp | 0.9%-6.7pp | 7.5% |
| Return on Equity | 5.3%+3.3pp | 2.0%-1.8pp | 3.8% | N/A | N/A | 4.0%+3.8pp | 0.3%-2.0pp | 2.3% |
| Return on Assets | 1.9%+1.3pp | 0.6%-0.6pp | 1.2%+2.0pp | -0.8%-0.5pp | -0.3%-2.2pp | 2.0%+1.9pp | 0.1%-1.0pp | 1.1% |
| Current Ratio | 2.58+0.0 | 2.54-0.1 | 2.66-0.1 | 2.72-1.2 | 3.97+0.0 | 3.95+0.4 | 3.57-0.1 | 3.70 |
| Debt-to-Equity | 0.59-0.1 | 0.69-0.0 | 0.73-0.0 | 0.77+0.1 | 0.620.0 | 0.63-0.0 | 0.660.0 | 0.66 |
| FCF Margin | 16.7%-17.3pp | 34.0%+17.5pp | 16.5%+9.4pp | 7.1%-2.3pp | 9.4%-0.6pp | 10.0%-22.3pp | 32.3%+9.2pp | 23.1% |
Similar Companies
Frequently Asked Questions
What is Ani Pharmaceutic's annual revenue?
Ani Pharmaceutic (ANIP) reported $614.4M in total revenue for fiscal year 2024. This represents a 26.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ani Pharmaceutic's revenue growing?
Ani Pharmaceutic (ANIP) revenue grew by 26.2% year-over-year, from $486.8M to $614.4M in fiscal year 2024.
Is Ani Pharmaceutic profitable?
No, Ani Pharmaceutic (ANIP) reported a net income of -$18.5M in fiscal year 2024, with a net profit margin of -3.0%.
What is Ani Pharmaceutic's earnings per share (EPS)?
Ani Pharmaceutic (ANIP) reported diluted earnings per share of $-1.04 for fiscal year 2024. This represents a -222.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Ani Pharmaceutic's EBITDA?
Ani Pharmaceutic (ANIP) had EBITDA of $68.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Ani Pharmaceutic have?
As of fiscal year 2024, Ani Pharmaceutic (ANIP) had $144.9M in cash and equivalents against $309.1M in long-term debt.
What is Ani Pharmaceutic's gross margin?
Ani Pharmaceutic (ANIP) had a gross margin of 59.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Ani Pharmaceutic's operating margin?
Ani Pharmaceutic (ANIP) had an operating margin of 0.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Ani Pharmaceutic's net profit margin?
Ani Pharmaceutic (ANIP) had a net profit margin of -3.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Ani Pharmaceutic's free cash flow?
Ani Pharmaceutic (ANIP) generated $47.8M in free cash flow during fiscal year 2024. This represents a -56.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ani Pharmaceutic's operating cash flow?
Ani Pharmaceutic (ANIP) generated $64.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Ani Pharmaceutic's total assets?
Ani Pharmaceutic (ANIP) had $1.3B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Ani Pharmaceutic's capital expenditures?
Ani Pharmaceutic (ANIP) invested $16.2M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Ani Pharmaceutic spend on research and development?
Ani Pharmaceutic (ANIP) invested $44.6M in research and development during fiscal year 2024.
Does Ani Pharmaceutic buy back shares?
Yes, Ani Pharmaceutic (ANIP) spent $11.0M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
What is Ani Pharmaceutic's current ratio?
Ani Pharmaceutic (ANIP) had a current ratio of 2.72 as of fiscal year 2024, which is generally considered healthy.
What is Ani Pharmaceutic's debt-to-equity ratio?
Ani Pharmaceutic (ANIP) had a debt-to-equity ratio of 0.77 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ani Pharmaceutic's return on assets (ROA)?
Ani Pharmaceutic (ANIP) had a return on assets of -1.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Ani Pharmaceutic's Altman Z-Score?
Ani Pharmaceutic (ANIP) has an Altman Z-Score of 1.90, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ani Pharmaceutic's Piotroski F-Score?
Ani Pharmaceutic (ANIP) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ani Pharmaceutic's earnings high quality?
Ani Pharmaceutic (ANIP) has an earnings quality ratio of -3.46x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Ani Pharmaceutic cover its interest payments?
Ani Pharmaceutic (ANIP) has an interest coverage ratio of 0.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Ani Pharmaceutic?
Ani Pharmaceutic (ANIP) scores 62 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.